key: cord-0740194-br0hhzmn authors: Wanner, Nicola; Andrieux, Geoffroy; Badia-i-Mompel, Pau; Edler, Carolin; Pfefferle, Susanne; Lindenmeyer, Maja T.; Schmidt-Lauber, Christian; Czogalla, Jan; Wong, Milagros N.; Okabayashi, Yusuke; Braun, Fabian; Lütgehetmann, Marc; Meister, Elisabeth; Lu, Shun; Noriega, Maria L. M.; Günther, Thomas; Grundhoff, Adam; Fischer, Nicole; Bräuninger, Hanna; Lindner, Diana; Westermann, Dirk; Haas, Fabian; Roedl, Kevin; Kluge, Stefan; Addo, Marylyn M.; Huber, Samuel; Lohse, Ansgar W.; Reiser, Jochen; Ondruschka, Benjamin; Sperhake, Jan P.; Saez-Rodriguez, Julio; Boerries, Melanie; Hayek, Salim S.; Aepfelbacher, Martin; Scaturro, Pietro; Puelles, Victor G.; Huber, Tobias B. title: Molecular consequences of SARS-CoV-2 liver tropism date: 2022-03-28 journal: Nat Metab DOI: 10.1038/s42255-022-00552-6 sha: 60b49c1dd8ca80c4bc455b8ac22fae1fce2c3d8c doc_id: 740194 cord_uid: br0hhzmn Extrapulmonary manifestations of COVID-19 have gained attention due to their links to clinical outcomes and their potential long-term sequelae(1). Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) displays tropism towards several organs, including the heart and kidney. Whether it also directly affects the liver has been debated(2,3). Here we provide clinical, histopathological, molecular and bioinformatic evidence for the hepatic tropism of SARS-CoV-2. We find that liver injury, indicated by a high frequency of abnormal liver function tests, is a common clinical feature of COVID-19 in two independent cohorts of patients with COVID-19 requiring hospitalization. Using autopsy samples obtained from a third patient cohort, we provide multiple levels of evidence for SARS-CoV-2 liver tropism, including viral RNA detection in 69% of autopsy liver specimens, and successful isolation of infectious SARS-CoV-2 from liver tissue postmortem. Furthermore, we identify transcription-, proteomic- and transcription factor-based activity profiles in hepatic autopsy samples, revealing similarities to the signatures associated with multiple other viral infections of the human liver. Together, we provide a comprehensive multimodal analysis of SARS-CoV-2 liver tropism, which increases our understanding of the molecular consequences of severe COVID-19 and could be useful for the identification of organ-specific pharmacological targets. Extrapulmonary manifestations of COVID-19 have gained attention due to their links to clinical outcomes and their potential long-term sequelae 1 . Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) displays tropism towards several organs, including the heart and kidney. Whether it also directly affects the liver has been debated 2,3 . Here we provide clinical, histopathological, molecular and bioinformatic evidence for the hepatic tropism of SARS-CoV-2. We find that liver injury, indicated by a high frequency of abnormal liver function tests, is a common clinical feature of COVID-19 in two independent cohorts of patients with COVID-19 requiring hospitalization. Using autopsy samples obtained from a third patient cohort, we provide multiple levels of evidence for SARS-CoV-2 liver tropism, including viral RNA detection in 69% of autopsy liver specimens, and successful isolation of infectious SARS-CoV-2 from liver tissue postmortem. Furthermore, we identify transcription-, proteomic-and transcription factor-based activity profiles in hepatic autopsy samples, revealing similarities to the signatures associated with multiple other viral infections of the human liver. Together, we provide a comprehensive multimodal analysis of SARS-CoV-2 liver tropism, which increases our understanding of the molecular consequences of severe COVID-19 and could be useful for the identification of organ-specific pharmacological targets. In this study, we examined three patient cohorts to characterize severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)-associated liver injury and infection. First, a clinical cohort (Hamburg; cohort 1, n = 99) was used to examine changes in liver function tests (LFTs) in patients admitted to hospital due to coronavirus disease 2019 (COVID- 19) and those who were diagnosed with COVID-19 during hospitalization (Fig. 1a) ; 42% of these patients were at least 65 years old, 70% were males, only 23% had at least 3 coexisting conditions (Source Data Fig. 1 ). Among patients admitted due to COVID-19 (n = 72), raised aspartate aminotransferase (AST) and alanine aminotransferase (ALT) were shown in 63 and 39% of cases (Fig. 1b) , respectively despite the low frequency of liver disease (1.4%), confirming previous studies [4] [5] [6] [7] [8] [9] [10] [11] . Next, we analysed a subgroup of patients that were admitted to hospital due to alternative diagnoses (n = 27) and suffered from nosocomial SARS-CoV-2 infection. Both AST and ALT were significantly increased after the diagnosis of COVID-19 (Fig. 1c) . While the percentage of patients with raised ALT almost doubled before and after COVID-19 diagnosis (33 versus 59%), the percentage of patients with elevated AST almost tripled (22 versus 67%) (Fig. 1d ). Next, we evaluated a large validation cohort of patients admitted to hospital due to COVID-19 (Michigan; cohort 2, n = 1,219) (Fig. 1e) ; 44% of patients were at least 65 years old, 57% were males and only 16% had at least 3 coexisting conditions (Supplementary Table 1 ). Importantly, 57% (n = 699) of patients showed elevations of AST and 37% (n = 452) of ALT at admission (Fig. 1e) . Furthermore, LFT elevations at admission and during the second week of hospitalization were associated with mortality ( Fig. 1f) , raising questions about their role in disease severity. Together, these observations clearly highlight hepatic injury as an important clinical feature of patients with COVID-19 requiring hospitalization. It has been postulated that LFT elevations in hospitalized patients with COVID-19 may result from systemic inflammation or severe cellular stress (for example, hypoxia), as generally observed in critically ill patients 9 . However, an autopsy study reported ultrastructural evidence of SARS-CoV-2 (ref. 12 ), and a second study reported histopathological findings in a liver biopsy of a patient with abnormal liver enzymes, including no obvious inflammation in the portal area, with normal description of the interlobular bile duct, interlobular vein, interlobular artery and hepatocytes with minimal inflammatory cell infiltration 11 . Given that liver biopsies are not routinely performed in patients with COVID-19 with altered LFTs, we evaluated a third cohort (cohort 3, n = 45 autopsy cases) in search of direct evidence of liver infection (Supplementary Table 2 ); 73% (n = 33) were older than 65, 69% (n = 31) had at least 3 coexisting conditions and 62% (n = 28) were males, matching the demographic characteristics linked to severe COVID-19. SARS-CoV-2 RNA was detected using quantitative PCR with reverse transcription (RT-qPCR) targeting the E gene in 69% of cases (n = 31) (Fig. 2a) , which was more frequently associated with older age, male sex and multiple coexisting conditions, as shown in previous reports 2, 13, 14 . Pathology assessment only revealed signs of shock, probably due to severe systemic disease, and adipose changes without classical signs of hepatitis or significant immune infiltration (n = 18; Extended Data Fig. 1 ). However, a combination of indirect immunofluorescence and high-resolution confocal microscopy identified hepatic expression of angiotensin-converting enzyme 2 (ACE2), the main cellular receptor of SARS-CoV-2 ( Fig. 2b and Extended Data Fig. 2 ; n = 5 liver samples), and SARS-CoV-2 spike protein ( Fig. 2c and Extended Data Fig. 3, n = 3 examples) . In addition, SARS-CoV-2 RNA was also found in hepatic cells with in situ hybridization (Supplementary Fig. 1 ; n = 4, that is, n = 2 SARS-CoV-2 PCR + and n = 2 controls (Ctrls)), confirming the spatial location of SARS-CoV-2 in the human liver using multiple techniques that complement the findings of previous studies 12, 15 . To provide additional context, we first compared the levels of SARS-CoV-2 RNA copies per cell between airway samples (previously reported in Puelles et al. 2 ) and a subset of autopsy livers, showing a similar range but a lower median viral RNA load in hepatic specimens (Supplementary Fig. 2a ; n = 18 lung, n = 16 pharynx and n = 18 liver), and we quantified the number of SARS-CoV-2 spike-positive cells in a small subset of our autopsy samples (n = 6 liver samples, that is, n = 3 SARS-CoV-2 PCR + and n = 3 Ctrls with quantification provided in Supplementary Fig. 2b) , both of which may explain the lack of overt cytopathic changes (that is, hepatitis). Notably, we isolated infectious SARS-CoV-2 from 2 out of 3 autopsy livers and corresponding lungs, confirming the infectivity of postmortem liver tissue samples, leading to a 1,000 time increase in viral RNA after 48 h of cell infection in vitro (Fig. 2d) , as previously reported in the kidney 13 . Together, our data provide spatial and functional evidence of SARS-CoV-2 hepatic tropism, at least in cases of fatal COVID-19. Next, we aimed to determine the molecular changes associated with SARS-CoV-2 liver tropism. Thus, liver tissues from a subset of COVID-19 autopsies were selected for transcriptomic and proteomic analyses (n = 11; transcriptomics, that is, Ctrls) to account for pleiotropic effects resulting from autopsy-related collection and storage. The groups were similar in terms of age, sex and number of coexisting conditions (Supplementary Table 3 ). First, transcriptomic profiling confirmed the expression of known SARS-CoV-2 entry receptors and facilitators in the liver autopsy samples (Extended Data Fig. 4 ), including ACE2, transmembrane protease serine 2 (TMPRSS2), procathepsin L and Ras-related protein Rab-7a 16, 17 . Importantly, a direct comparison to a publicly available dataset 18 contextualized the expression of these facilitators in relation to other organs, where liver samples showed similar expression levels as the lung, only surpassed by the kidney and small intestine, suggesting that hepatic tissue is susceptible to SARS-CoV-2 infection. Then, we detected SARS-CoV-2 subgenomic RNA within our own dataset and identified two samples out of six with values in the range of the infected respiratory tract, tracing SARS-CoV-2 to the liver by another independent methodology (Extended Data Fig. 5 ). Transcriptional changes associated with SARS-CoV-2 hepatic tropism revealed a significant upregulation of type I and II interferon (IFN) responses ( Fig. 2f and Extended Data Fig. 6 ). Gene Ontology (GO) analysis confirmed upregulation of IFN and viral responses and increases in lipid and phospholipid metabolic processes (Extended Data Fig. 7 ), supporting a recent study linking perturbations of lipid metabolism with SARS-CoV-2 infection 19 . Importantly, these findings were also consistent at a single patient level (Fig. 2g ) and within single gene sets (Fig. 2h,i) . While SARS-CoV-2 has developed strategies to evade IFN responses, leading to relatively weak type I and III IFN induction in host cells 20 , a recent study showed a high expression level of IFN-stimulated genes in patients with a high SARS-CoV-2 viral load and high levels of pro-inflammatory cytokines but relatively intact lung morphology 21 . These observations are in agreement with our findings, supporting upregulated IFN responses in tissues with traces of SARS-CoV-2 RNA and without classical cytopathic changes. In addition, we also identified that components of IFN-related JAK-STAT signalling ( Supplementary Fig. 3 ), and other central cellular processes involved in lipid/cholesterol synthesis, including terpenoid and steroid biosynthesis were all modulated in patients with SARS-CoV-2 liver tropism. Altogether, these data provide a comprehensive framework to understand the molecular consequences of SARS-CoV-2-mediated liver injury. Global proteomic profiling in hepatic tissues of the same autopsy cohort showed substantial regulation of IFN, viral and in particular SARS-CoV-2 responses ( Fig. 3a and Source Data Fig. 3 ). Protein ontology analysis revealed upregulation of IFN signalling and downregulation of basic biological processes, including oxidation reduction, oxidative phosphorylation and cellular respiration (Fig. 3b ). Type I IFN responses were confirmed at the single patient level (Fig. 3c ). Gene/protein sets for hallmark 'interferon-α (IFN-α) response' (R = 0.65, P < 0.05; Fig. 3d ) and the GO Biological Process 'defence response to virus' (R = 0.71, P < 0.05; Fig. 3e ), as well as single gene/protein analysis for IFN-inducible genes (R = 0.74-0.87, P < 0.05; Fig. 3f ), showed strong associations between transcriptomic and proteomic profiles, highlighting a coherent modulation of SARS-CoV-2-related pathways at the transcriptional and translational level. Furthermore, transcription factor activity profiling (Fig. 3g) provided individual (Fig. 3h ) and global (Fig. 3i) signatures that combined transcription factor upregulation (for example, signal transducer and activator of transcription 2 (STAT2), a signal transducer and activator of transcription that mediates signalling by type I IFNs) and downregulation (that is, nuclear receptor corepressor 2 (N-CoR2), which aids histone deacetylases to modify chromatin structure, thus preventing basal transcriptional activity). Canonical pathway analysis confirmed upregulation of immune-mediated, The colour coding represents the number of genes within each gene set. c, Row-wise scaled intensity (z-score) heatmap showing genes from the 'IFN-α response' gene set. Genes were ranked according to the log 2 fold change, which is indicated on the right. *P adj < 0.05. Within each group, samples were clustered based on Euclidean distance. d,e, mRNA versus protein-positive versus negative fold change scatter plot of gene sets 'hallmark IFN-α response' (d) and 'GO defense response to virus' (e). Each dot represents a gene that belongs to the gene set. The blue line represents the linear regression between mRNA and protein fold changes. f, mRNA versus protein intensity scatter plot of the genes IFIT2, IFIT3, OAS2 and MX1. Each dot represents a single sample, colour-coded based on the groups: white, green and purple for Ctrl, negative and positive, respectively. The blue line represents the linear regression between mRNA and protein-normalized intensities. g, Transcription factor analysis revealed differential transcription factor usage in Ctrl, COVID-19 liver negative and liver positive samples. h, Heatmap of differentially regulated transcription factors per sample (positive: n = 7; negative: n = 6; Ctrl: n = 6). i, Summary of the mean transcription factor analysis. ≥65 years, sex, 3 or more coexisting conditions and SARS-CoV-2 liver tropism (PCR + liver). b, Immunofluorescence images show the presence of the SARS-CoV-2 receptor ACE2 in hepatic cells (that is, Kupffer cells). Staining was performed in samples from five different patients (data shown in Extended Data Fig. 2) . c, SARS-CoV-2 spike protein detection in autopsy liver tissues (that is, Kupffer cells and hepatocytes). d, Successful SARS-CoV-2 isolation in postmortem livers and respective lungs from two of three autopsy cases, showing increases in SARS-CoV-2 RNA levels in the supernatants of infected cells (43) (44) (45) refers to the number sequence in a). e, Schematic of autopsy tissue selection for molecular profiling. f, Generally applicable gene set enrichment (GAGE) analysis of gene sets significantly regulated between liver PCR-positive, PCR-negative and Ctrl conditions. g, Single-sample jitter plot for gene sets significant (P adj < 0.05) in at least 1 sample and significant difference between the PCR-positive and PCR-negative groups (Wilcoxon signed-rank test, P < 0.05). Box plot (box extending from the 25th to the 75th percentile with the median shown as a line in the middle and the whiskers indicating the smallest and largest values) showing the most relevant pathways from Consensus PathDB. Pathways were ranked according to the average difference between PCR-positive and PCR-negative. Each dot represents the enrichment score from the single-sample analysis. Two-sided Wilcoxon signed-rank tests were performed for statistical significance, including IFN-α response (P = 0.004329004), interferon-γ (IFN-γ) response (P = 0.017316017) and Notch signalling (P = 0.017316017). h, Single-sample enrichment barcode illustrating the distribution of the hallmark gene set 'IFN-α response' in every single sample. Genes were ranked according to their normalized TPM value. The colour coding represents the enrichment score of the gene set during a random walk over the ranked list of genes. Samples were divided into PCR-positive and PCR-negative and then ordered from left to right based on their enrichment score, from high to low. i, Row-wise scaled intensity (z-score) heatmap showing genes from the IFN-α response gene set. Genes were ranked according to the log 2 fold change, which is indicated on the right. *P adj < 0.05. Within each group, samples were clustered based on Euclidean distance. Scale bars, 10 μm. IFN and JAK-STAT-related responses (Extended Data Fig. 8a) , as well as downregulation of glucose and carbohydrate metabolism in association with liver tropism (Extended Data Fig. 8b) . Interestingly, modulation of JAK-STAT signalling has been proposed to target SARS-CoV-2 viral entry and replication 22 in a study that dissected SARS-CoV-2 infectivity using organotypic three-dimensional cultures of primary human liver cells. The clinical and molecular data from our study suggest that SARS-CoV-2-mediated liver injury is comparable to previously characterized hepatotropic viruses. For this reason, we compared IFIT3 IFIT2 CMPK2 UBE2L6 ISG15 PNPT1 ADAR EIF2AK2 IFITM3 CNP MX1 TRIM21 HLA-C C1S CD74 TRIM25 LGALS3BP B2M LAP3 IFI35 PSME2 PSME1 PSMB8 PSMA3 GMPR IFI30 L3 L8 L14 L16 L20 L4 L5 L6 L12 CoR2 BHLHE22 E2F6 ZNF263 NR2F6 MNT MXI1 MAFK OX6 NR4A1 MAFG NONO ARID2 KLF1 TF6 HNF4G MAX EBF1 ARID1A OX13 NCOA2 ZNF384 AF1 ARID1B MAFB NR2F1 KMT2A TF7 NCOA3 PRDM14 JUNB TBX21 CTCFL NFE2 IRF2 ELK1 THAP1 TCF12 POU4F2 TAT1 ZNF143 POU2F2 TAT2 CoR2 BHLHE22 E2F6 ZNF263 NR2F6 MNT MXI1 MAFK SOX6 NR4A1 MAFG NONO ARID2 KLF1 ATF6 HNF4G MAX EBF1 ARID1A SOX13 NCOA2 ZNF384 TAF1 ARID1B MAFB NR2F1 KMT2A ATF7 NCOA3 PRDM14 JUNB TBX21 CTCFL NFE2 IRF2 ELK1 THAP1 TCF12 POU4F2 STAT1 ZNF143 POU2F2 STAT2 K94 L24 L25 L26 L27 L30 L33 L14 L16 L20 L3 L8 L1 L12 L13 L4 L5 L6 ARID2 KLF1 ATF6 HNF4G MAX EBF1 ARID1A SOX13 NCOA2 ZNF384 TAF1 ARID1B MAFB NR2F1 KMT2A ATF7 NCOA3 PRDM14 JUNB TBX21 CTCFL NFE2 IRF2 ELK1 THAP1 TCF12 POU4F2 STAT1 ZNF143 POU2F2 STAT2 COVID- publicly available datasets containing bulk RNA sequencing (RNA-seq) data from liver tissue samples from patients with hepatitis C virus (HCV) 23 , human immunodeficiency virus (HIV) 24 and hepatitis B virus (HBV) 25 via gene set enrichment analysis (GSEA) (Fig. 4a) . While our literature search was carefully performed, it was not possible to find studies that could be perfectly matched our study demographics (for example, our population was notably older than the other three studies as per the demographic trends of fatal COVID-19; Supplementary Table 4 ). Interestingly, and despite of multiple methodological limitations, all three infections affecting the liver, including HBV (Fig. 4b) , HCV (Fig. 4c) and HIV (Fig. 4d) , showed overlapping gene expression patterns with our proposed SARS-CoV-2 signature. Specific examples include upregulation of IFN signalling gene sets (Fig. 4e) , especially types I, II and III IFN responses (Fig. 4f) , and downregulation of viral gene expression and related cellular functions (that is, translational initiation and peptide metabolic processes) (Fig. 4g) . Pathway analysis also revealed remarkable overlap between SARS-CoV-2 and HCV (13 of 20 pathways for upregulated; Fig. 4h ; 8 of 20 pathways for downregulated; Fig. 4i ). In addition, we identified similar transcription factor use in livers from patients with severe COVID-19 and patients with liver steatosis and HIV, inactive carriers of HBV and chronic HCV (Fig. 4j) . Taken together, this comparative analysis highlights a shared molecular signature between SARS-CoV-2 and multiple viruses with well-characterized patterns of liver injury. Since the topic of SARS-CoV-2 hepatic tropism has been highly debated 3 , we aimed to tackle this question from multiple perspectives, including clinical (two large independent patient cohorts that showcase COVID-19-associated liver injury), histopathological (identification of SARS-CoV-2 at the RNA and protein levels with high spatial resolution), virological (RT-qPCR in human autopsy samples and isolation of SARS-CoV-2 from human autopsy liver specimens), molecular (transcriptomic, proteomic and transcription factor activity use profiling, indicating the presence of SARS-CoV-2 in association with significant tissue responses) and bioinformatic (detection of subgenomic RNA and data validation with external public datasets of virus-mediated hepatic injury). Despite all these layers of evidence supporting SARS-CoV-2 hepatic tropism, the exact mechanism of infection is unclear. Our findings show that the human liver is susceptible to SARS-CoV-2 infection since cell entry receptors and facilitators are clearly expressed in hepatic cells. However, we observed a mismatch between the expression of the ACE2 protein, mostly observed in Kupffer cells, and the location of the SARS-CoV-2 spike protein, which was observed in Kupffer and parenchymal cells (for example, hepatocytes). In this context, it is worth considering a recent study that proposed high-density lipoprotein scavenger receptor class B member 1 (SRB1) as a cell entry facilitator for SARS-CoV-2. SRB1 acts as a critical receptor that affects HCV entry 26 , an infection that shares some molecular features with SARS-CoV-2 liver tropism. While Wei et al. 19 reported strong protein expression of SRB1 in the human liver, we confirmed messenger RNA expression of SCARB1 (SRB1 gene) in multiple human organs, showing the highest expression levels in the liver followed by the brain, small intestine, lung, kidney and muscle (Extended Data Fig. 9 ). In addition, we confirmed SRB1 protein expression on human hepatocytes and in association with the expression of SARS-CoV-2 spike protein (Extended Data Fig. 10 ). It is plausible that even if the expression of ACE2 in hepatocytes is relatively low at both RNA and protein levels, high levels of SRB1 may enhance the potential for SARS-CoV-2 entry. It is worth remembering that our observations represent a late 'snapshot' of a severe disease state and consequent multi-organ dysfunction (that is, severe COVID-19 leading to death), which provides a limited view affected by disease course, coexisting conditions, therapeutic interventions and postmortem processes. All these factors may influence our view of receptor expression patterns (for example, potential up/downregulation during infection), definition of cell-specific tropism (that is, severe injury to infected cells and local protein clearance) and even molecular signatures, which likely reflect profound cellular changes in neighbouring cells that have survived an active phase of SARS-CoV-2 tropism and could explain the common features between patients with severe COVID-19 and hepatotropic viruses (that is, HCV). Furthermore, our findings should be carefully considered in the context of lack of access to full clinical data in our large clinical cohorts, limiting our ability to rule out other causes of liver injury (for example, drug-mediated hepatoxicity), and relatively small sample sizes in our multi-omics experiments, which were mainly focused on patients who died due to severe COVID-19, raising questions about generalizability to mild and moderate cases. Despite this, a recent clinical study followed 443 non-hospitalized individuals for approximately 9.6 months after their first positive SARS-CoV-2 test, revealing signs of multi-organ injury 27 , which allows us to question the potential for similar molecular changes in mild and moderate forms of COVID-19. In summary, our findings provide multimodal evidence of SARS-CoV-2 human liver tropism and a molecular signature, featuring a strong upregulation of IFN responses, JAK-STAT signalling and liver-specific metabolic modulation. This unique human dataset can be used as a rational framework for future studies aiming to characterize the potential consequences of SARS-CoV-2 extrapulmonary manifestations and identify personalized therapeutic strategies. Tissue and data collection. Autopsies were performed at the Institute of Legal Medicine of the University Medical Center Hamburg-Eppendorf. From every liver specimen collected by the Institute of Legal Medicine, multiple randomly chosen small samples were available for different analyses. The ethics committee of the Hamburg Chamber of Physicians was informed about the study (nos. 2020-10353-BO-ff and PV7311). Ctrls included cases of sudden, non-infectious deaths. The postmortem interval was on average 6 d. Informed consent was obtained from a next of kin or legal representative for autopsy and tissue sampling. No compensation was paid. The study protocol for clinical data collection (patient cohorts) was approved by the institutional review board (IRB) of the University of Michigan (no. HUM00178971) and Hamburg (no. WF-052/20). The IRB approved a waiver of informed consent for this observational study. Tissue samples were systematically sampled during the autopsy procedure in 45 individuals. Automated nucleic acid extraction was performed according to the manufacturer's recommendations with whole process control (control kit; Roche), with a final elution volume of 100 μl. For virus quantification, a previously published assay was adopted with modifications using chimeric 2′-O-methyl RNA bases at the penultimate base of both primers (mG and mC) to reduce primer dimer formation 28 . The forward primer 5′-ACAGGTACGTTAATAGTTAATAGCmGT-3′ (400 nM end concentration), 5′-TATTGCAGCAGTACGCACAmCA-3′ (400 nM end concentration) and probe 5′-Fam-ACACTAGCC/ZEN/ATCCTTACTGCGCTTCG-Iowa Black FQ-3′ (100 nM end concentration) were used. Primer and probes were obtained from Integrated DNA Technologies. One-step RT-PCR (25 μl volume) was run on the LightCycler 480 system (Roche) using the one-step RNA control kit as master mix (Roche) and 5 μl of eluate. The Ct value for the target SARS-CoV-2 RNA (FAM) was determined using the second derivative maximum method. To quantify the standard in vitro-transcribed RNA, the E gene of SARS-CoV-2 was used. The standard was obtained via the European Virus Archive 4 . The linear range of the assay was between 1 × 10 3 and 1 × 10 9 copies ml −1 . β-Globin qPCR was performed with the commercial TaqMan primer set (catalogue no. 401846; Thermo Fisher Scientific) and Roche DNA control kit. The PCR was run on the LightCycler 480 system. The amount of DNA was normalized using a human DNA standard (KR0454). SARS-CoV-2 RNA levels in tissues were normalized to β-globin DNA. Histology, immunolabelling and quantification. Liver tissue was fixed in formaldehyde. Then, 2-μm slides were cut and haematoxylin and eosin, periodic acid-Schiff and Masson-Goldner stainings were performed. Expert pathology review was conducted by two independent and experienced pathologists. ACE2 and SARS-CoV-2 spike were detected in formalin-fixed paraffin-embedded sections using a protocol for indirect immunofluorescence and confocal microscopy 29, 30 . We used primary antibodies against ACE2 (dilution: 1:200, catalogue no. AF933; R&D Systems) and SARS-CoV/SARS-CoV-2 (COVID-19) (dilution 1:200, catalogue no. GTX632604; GeneTex), which were Letters NATURE METAbOlISM validated in previous studies 2, 13 . We also used a primary antibody against SRB1 (dilution 1:200, catalogue no. ab217318; Abcam). For quantification, and considering the size and degree of autolysis, we performed targeted sampling of five fields of view based on the presence of at least one SARS-CoV-2 spike + cell with a random location within the field; for Ctrls, five random fields were chosen from non-autolytic sites. Then, we quantified the number of SARS-CoV-2 spike + cells and the total number of complete nuclei per field, which allowed us to calculate a percentage of positive cells per field. Statistics were performed with Prism v.9.2.0 (GraphPad Software). In situ hybridization was carried out to detect virus RNA of SARS-CoV-2 on paraffin sections utilizing the RNAscope 2.5 HD detection kit (catalogue no. 322310; Advanced Cell Diagnostics) according to the manufacturer's instructions 31 . Briefly, tissue sections were deparaffinized in xylene followed by target retrieval at 95 °C for 10 min. Subsequently, internal peroxidase activity was quenched by hydrogen peroxide incubation for 10 min followed by permeabilization using protease plus treatment at 40 °C for 30 min. The SARS-CoV-2-specific RNAscope probe V-nCoV2019-S (catalogue no. 848561) was hybridized at 40 °C for 2 h. RNAscope probes specific for either the human ubiquitin C mRNA (catalogue no. 310041) or the bacterial dihydrodipicolinate reductase mRNA (catalogue no. 310043) were used as positive or negative Ctrl, respectively. The RNAscope signal was developed with 3,3′-diaminobenzidine and nuclei were counterstained with haematoxylin. Cell culture and virus isolation. Liver tissues were homogenized 32 GTEX data. Raw counts from several healthy tissues were downloaded directly from the GTEX portal (www.gtexportal.org) on 4 March 2020 35 . Differential analysis. Genes with a non-null count in at least two samples were selected. Raw counts were processed with the limma R package v.3.42.2 (ref. 36 ) and differentially regulated genes between PCR-positive and PCR-negative groups were identified after library size normalization. Both groups were compared to GTEX liver. A Benjamini-Hochberg-adjusted P < 0.05 was considered significant. Group-wise GSEA. GSEA was performed using the GAGE R package v.2.36.0 (ref. 37 ) with the Molecular Signatures Database (MSigDB) gene set v.7.1, comparing PCR-positive to PCR-negative groups. Both groups were also compared with GTEX liver. A Benjamini-Hochberg-adjusted P < 0.05 was considered significant. Single-sample GSEA. First, each sample was normalized to healthy liver tissue to depreciate the background noise and emphasize the true signal. Therefore, the average GTEX liver transcripts per kilobase million (TPM) intensity was subtracted for every single gene. In each sample, genes were ranked according to their normalized TPM value and used as input for single-sample enrichment analysis using the fgsea R package v.1.12.0 (ref. 38 ) with MSigDB gene set v.7.1 (ref. 39 ) and ConsensusPathDB v.34 (ref. 40 ). In all gene sets, the enrichment score was calculated based on a random walk over the ranked list of genes. The significance of the enrichment scores was assessed with 1,000 permutations. A Benjamini-Hochberg-adjusted P < 0.05 was considered significant. Kyoto Encyclopedia of Genes and Genomes pathways were created with PathView v.1.34.0 (ref. 41 ) with log 2 positive versus negative fold change. Detection of sgRNA. The relative fraction of single-guide RNAs (sgRNAs) was determined by identifying the leader sgRNA fusion containing sequencing reads normalized to read counts containing the genomic RNA leader sequence 42 . Pharyngeal swab data served as a positive control for the detection of sgRNA due to the high amount of replicating virus in this specimen. Swab sample data were reproduced from our own data 42 . Proteomic analysis. For sample preparation, paraffin-embedded liver samples were deparaffinized, resuspended in 100 μl lysis buffer (50% trifluoroethanol (TFE), 300 mM Tris-HCl, pH 8.0) and processed 43 . Briefly, samples were sonicated at 4 °C for 15 min ('high' settings on a Bioruptor; Diagenode), boiled at 95 °C for 90 min and sonicated again as described above. Cleared lysates were reduced/ alkylated (5 mM dithiothreitol, 25 mM chloroacetamide) for 1 h in the dark and concentrated on a vacuum centrifuge (45 min, 60 °C). A total of 50 µg proteins were digested overnight in digestion buffer (10% TFE containing trypsin/LysC (1:50 protein/protein ratio). Digestion was stopped with 1% trifluoroacetic acid (TFA) and peptides were purified on stage tips with two SDB-RPS Empore filter discs (3M) and resuspended in 2% acetonitrile (ACN)/0.1% TFA to a final concentration of 250 ng µl −1 . Ultra-high-performance liquid chromatography and trapped ion mobility spectrometry quadrupole time of flight settings. Samples were analysed on a nanoElute (plug-in v.1.1.0.27; Bruker) coupled to a trapped ion mobility spectrometry quadrupole time of flight (timsTOF Pro) (Bruker) equipped with a CaptiveSpray source. Peptides (500 ng) were injected into a Trap cartridge (5 mm × 300 μm, 5 μm C18; Thermo Fisher Scientific) and next separated on a 25 cm × 75 μm analytical column, 1.6 μm C18 beads with a packed emitter tip (IonOpticks). The column temperature was maintained at 50 °C using an integrated column oven (Sonation GmbH). The column was equilibrated using 4 column volumes before loading samples in 100% buffer A (99.9% Milli-Q water, 0.1% formic acid (FA)). Samples were separated at 400 nl min −1 using a linear gradient from 2 to 17% buffer B (99.9% ACN, 0.1% FA) over 60 min before ramping up to 25% (30 min), 37% (10 min) and 95% of buffer B (10 min) and sustained for 10 min (total separation method time, 120 min). The timsTOF Pro was operated in parallel accumulation-serial fragmentation (PASEF) mode using Compass Hystar v.5.0.36.0. Settings were as follows: mass range 100-1700 m/z, 1/K0 start 0.6 V⋅s/ cm 2 End 1.6 V⋅s/cm 2 ; ramp time 110.1 ms; lock duty cycle to 100%; capillary voltage 1,600 V; dry gas 3 l min −1 ; dry temperature 180 °C. The PASEF settings were: 10 tandem mass spectrometry (MS) scans (total cycle time, 1.27 s); charge range 0-5; active exclusion for 0.4 min; scheduling target intensity 10,000; intensity threshold 2,500; collision-induced dissociation energy 42 eV. Raw data processing and analysis. Raw MS data were processed with the MaxQuant software v.1.6.17 using the built-in Andromeda search engine to search against the human proteome (UniprotKB, release 2019_10) containing forward and reverse sequences concatenated with the SARS-CoV-2 polyprotein with the individual viral open reading frames manually annotated, and the label-free quantitation algorithm 44 . Additionally, the intensity-based absolute quantification (iBAQ) algorithm and match between runs option were used. In MaxQuant, carbamidomethylation was set as fixed and methionine oxidation and N-acetylation as variable modifications. Search peptide tolerance was set at 70 p.p.m. and the main search was set at 30 p.p.m. (other settings left as default). Experiment type was set as TIMS-DDA with no modification to the default settings. Search results were filtered with a false discovery rate of 0.01 for peptide and protein identification. The Perseus software v.1.6.10.4 was used to process the data further. Protein tables were filtered to eliminate the identifications from the reverse database and common contaminants. When analysing the MS data, only proteins identified on the basis of at least one peptide and a minimum of three quantitation events in at least one experimental group were considered. The iBAQ protein intensity values were normalized against the median intensity of each sample (using only peptides with recorded intensity values across all samples and biological replicates) and log-transformed; missing values were filled by imputation with random numbers drawn from a normal distribution calculated for each sample 45 . Differential analysis and GSEA were performed as described above on mRNA. Data integration. The mRNA and protein datasets were integrated and the correlation analysis was performed based on two different approaches: gene-wise and sample-wise. Gene-wise. Spearman's correlation between mRNA and protein across all samples was calculated for every single gene separately. For each gene, lower-and upper-tail P values were calculated from the empirical cumulative distribution function (ECDF). Significantly highly correlated genes (upper-tail P < 0.05) were selected to perform GSEA using Fisher's exact test on the MSigDB. A Benjamini-Hochberg-adjusted P < 0.05 was considered significant. Sample-wise. For every single gene, we calculated the average fold change between positive and negative. The gene set-specific correlation was assessed by first selecting the genes that belonged to a given gene set, then by calculating the mRNA fold change versus the protein fold change Spearman's correlation of these genes. To estimate the significance of the correlation for one gene set, correlation values were also calculated from 10,000 random sets of genes, using the same number of genes as the given gene set. Finally, the ECDF was used to return lower-and upper-tail P values. Transcription factor analysis. Functional analysis was performed with the DoRothEA package (1.4.1) 46 for transcription factor activity and the PROGENy package (1.14.0) 47 for pathway activity. To test the difference in activities, a factorial experiment was designed for each modality using the limma package. In both functional types, the first factor was the infection status of the patient (COVID-19 + /COVID-19 − ) and the second was if there were traces of the virus in their liver (PCR + /PCR − ). Thus, in total there were three factor combinations: a healthy patient (COVID-19 − /PCR − : Ctrl); an early-stage infection (COVID-19 + /PCR − : negative); and a late-stage infection (COVID-19 + /PCR + : positive). A linear model Letters NATURE METAbOlISM was fitted for each transcription factor and pathway activity to obtain coefficients for each factorial combination. Then, these coefficients were used to compute three contrasts: effect of COVID-19 + /PCR − based on COVID-19 − /PCR − samples (negative versus Ctrl); effects of COVID-19 + /PCR− based on COVID-19 − /PCR − samples (positive versus Ctrl); and the difference between these two comparisons (positive versus negative). The first and second contrasts were aimed at detecting systematic changes in activity when an early or late-stage COVID-19 infection was taking place. However, the third contrast was aimed at detecting the specific difference in activity between late-stage and early-stage infection. The sign of the obtained coefficients can be interpreted as an increase or decrease of the mean activity for a given comparison, each with an associated probability. Reporting Summary. Further information on research design is available in the Nature Research Reporting Summary linked to this article. The RNA-seq raw and processed data have been deposited at the University Hamburg Research Data Repository (https://www.fdr.uni-hamburg.de/) with the following identifiers: https://doi.org/10.25592/uhhfdm.8358 and https://doi. org/10.25592/uhhfdm.8372. The mass spectrometry-based proteomics data have been deposited at the ProteomeXchange Consortium (http://proteomecentral. proteomexchange.org) via the PRIDE partner repository with the following dataset identifier: PXD022789. Source data are provided with this paper. Extrapulmonary manifestations of COVID-19 Multiorgan and renal tropism of SARS-CoV-2 Pathophysiological mechanisms of liver injury in COVID-19 Manifestations and prognosis of gastrointestinal and liver involvement in patients with COVID-19: a systematic review and meta-analysis Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study Clinical characteristics of coronavirus disease 2019 in China Clinical features of patients infected with 2019 novel coronavirus in Wuhan Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan, China Liver injury in COVID-19: management and challenges Longitudinal analysis of the utility of liver biochemistry as prognostic markers in hospitalized patients with corona virus disease 2019 COVID-19: abnormal liver function tests SARS-CoV-2 infection of the liver directly contributes to hepatic impairment in patients with COVID-19 SARS-CoV-2 renal tropism associates with acute kidney injury Association of SARS-CoV-2 renal tropism with acute kidney injury-authors' reply SARS-CoV-2 infects and replicates in cells of the human endocrine and exocrine pancreas Mechanisms of SARS-CoV-2 transmission and pathogenesis Identification of required host factors for SARS-CoV-2 infection in human cells The Genotype-Tissue Expression (GTEx) project HDL-scavenger receptor B type 1 facilitates SARS-CoV-2 entry Imbalanced host response to SARS-CoV-2 drives development of COVID-19 Two distinct immunopathological profiles in autopsy lungs of COVID-19 JAK inhibition reduces SARS-CoV-2 liver infectivity and modulates inflammatory responses to reduce morbidity and mortality Transcriptional response to hepatitis C virus infection and interferon-alpha treatment in the human liver Effects of tesamorelin on hepatic transcriptomic signatures in HIV-associated NAFLD Transcriptomic analysis of livers of inactive carrier HBV patients with differential HBsAg Role of scavenger receptor class B type I in hepatitis C virus entry: kinetics and molecular determinants Multi-organ assessment in mainly non-hospitalized individuals after SARS-CoV-2 infection: the Hamburg City Health Study COVID programme Evaluation of a quantitative RT-PCR assay for the detection of the emerging coronavirus SARS-CoV-2 using a high throughput system The tetraspanin CD9 controls migration and proliferation of parietal epithelial cells and glomerular disease progression mTOR-mediated podocyte hypertrophy regulates glomerular integrity in mice and humans Association of cardiac infection with SARS-CoV-2 in confirmed COVID-19 autopsy cases Autopsy findings and venous thromboembolism in patients with COVID-19: a prospective cohort study STAR: ultrafast universal RNA-seq aligner HTSeq-a Python framework to work with high-throughput sequencing data GTEx Consortium The Genotype-Tissue Expression (GTEx) project limma powers differential expression analyses for RNA-sequencing and microarray studies GAGE: generally applicable gene set enrichment for pathway analysis Fast gene set enrichment analysis Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles The ConsensusPathDB interaction database: 2013 update Pathview: an R/Bioconductor package for pathway-based data integration and visualization SARS coronavirus-2 variant tracing within the first coronavirus disease 19 clusters in northern Germany A streamlined mass spectrometry-based proteomics workflow for large-scale FFPE tissue analysis The MaxQuant computational platform for mass spectrometry-based shotgun proteomics The Perseus computational platform for comprehensive analysis of (prote)omics data Benchmark and integration of resources for the estimation of human transcription factor activities Perturbation-response genes reveal signaling footprints in cancer gene expression ) and Federal Ministry for Education and Research, Germany. M.A. received funding from German Center for Infection Research (grant nos is supported by NHLBI 1R01HL153384-01 Total number of SARS-CoV-2-positive reads divided by total number of human reads (*1000) shows a higher number of reads aligning to the SARS-CoV-2 genome in SARS-CoV-2 liver POS samples than in SARS-CoV-2 liver NEG samples and controls. *, p-value = 0.0122 (Mann-Whitney test, two-tailed) Extended Data Fig. 8 | Canonical pathway analysis. a, Transcription factor analysis reveals differential transcription factor usage in CTL, COVID-19 liver NEG and liver POS samples. Summary of mean pathway activity in each infection status. b, Canonical pathways up (+) or down (-) regulated This work was supported by the following grants: CRC/1192 to V.G.P. and N.W.; SC 314/1-1 to P. Open access funding provided by Universitätsklinikum Hamburg-Eppendorf (UKE). The authors declare no competing interests. Extended data is available for this paper at https://doi.org/10.1038/s42255-022-00552-6. The online version contains supplementary material available at https://doi.org/10.1038/s42255-022-00552-6.Correspondence and requests for materials should be addressed to Victor G. Puelles or Tobias B. Huber.